- IAVI's extensive clinical trial experience will be combined with GreenLight COVID-19 vaccine candidate.
- Goal is to broaden and accelerate access to messenger RNA (mRNA) COVID-19 vaccines.
- Phase 1 trial planned for late Q1 2022.
- Plan speeds creation of vaccines in Africa, for Africa, and suitable for use in low-income countries globally.
PR Newswire
NEW YORK, Nov. 30, 2021